This non-gated CAR-T demonstrated “on-target, on-tumor” cytotoxicity to CD93 + AML cells, while “on-target, off-tumor” effect to CD93 + immortalized human umbilical vein endothelial cells which was engineered to stably express truncated CD19, thus killing the AML cells but avoiding the toxicity to endothelial cell. Here, CD19 is linked to neoplasm.